Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Brand (QFT-Plus), By Test Type, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Brand (QFT-Plus), By Test Type, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030


Latent Tuberculosis Infection Detection Market Growth & Trends

The global latent tuberculosis infection detection market size is expected to reach USD 2.63 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.44% from 2024 to 2030. The increased risk of developing active disease from latent tuberculosis infection (LTBI) coupled with the surge in the geriatric population globally is one of the major driving factors for the market growth. In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection is another factor contributing to market expansion. For instance, in July 2021, the UKHSA and NHS of England launched a 5-year plan to decrease TB cases in the country.

The market growth is fueled by the increase in the geriatric population across the globe. For instance, according to the elderly population report of America’s Health Rankings 2021, more than 54 million population aged more than 65 years in the U.S. which accounts for 16.5% of the country’s population. The geriatric population is highly susceptible to developing latent TB infection. Policymakers and public health officials are making improvements in policies to improve the health of older in the country.

Furthermore, ongoing funding activities by leading organizations to promote the diagnosis and testing for tuberculosis are also expected to fuel market growth. For instance, Unitaid is a leading health agency engaged in discovering quick solutions for diseases. In September 2022, the Unitaid launched funding of USD 30 million to boost tuberculosis detection. This funding will support the development of same-day tests and also help in the development of novel diagnostic technologies for tuberculosis.

Similarly, the Global Fund provides support and funding for the management of infectious diseases such as tuberculosis, malaria, and HIV. The organization provides around 76% of global financing for tuberculosis and it has invested around USD 8.5 billion for the management of tuberculosis. Furthermore, in August 2021, the Global Fund provide funds to FIND for the advancement of TB diagnosis and prevention in India. This investment optimized laboratory quality for early diagnosis of TB and improved tuberculosis diagnostic capacity in the country.

In addition, the rising testing efforts globally to promote the diagnosis of TB infection are expected to support market expansion. For instance, in March 2022, QIAGEN N.V. announced that the company has sold 100 million QuantiFERON blood tests since its launch. After this, the company decided to expand QuantiFERON to reach more patients across the globe. Moreover, various strategic initiatives undertaken by leading players to enhance their market share are another factor facilitating market expansion. For instance, in October 2021, QIAGEN announced CE mark approval and roll-out of the QIAreach QuantiFERON-TB test for tuberculosis infection diagnosis.

Latent Tuberculosis Infection Detection Market Report Highlights
  • In test type, the IGRA segment is expected to grow at the fastest rate over the forecast period owing to increasing recommendations for IGRAs from various public health authorities
  • Based on application segment, the PLHIV accounted for the largest revenue share in 2023 due to the rising risk of developing TB in people suffering from HIV infection
  • The diagnostic laboratories segment was the highest revenue contributor in 2023. Whereas the academic and research institutions segment is expected to exhibit the fastest CAGR during the projected period
  • Asia Pacific is expected to exhibit the fastest growth over the forecast period due to the rising investments by market players and increasing research activities in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Brand
1.2.2. Test Type
1.2.3. Application
1.2.4. End-use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Brand and test type outlook
2.2.2. Application and end-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing risk of developing active tuberculosis infection from LTBI
3.2.1.2. Increasing funding programs to promote TB diagnosis
3.2.1.3. Favorable government initiatives for combating TB
3.2.1.4. Surge in geriatric population
3.2.2. Market restraint analysis
3.2.2.1. Presence of stringent rules and regulations pertaining to diagnosis
3.2.3. Market opportunity analysis
3.2.4. Unmet need analysis
3.3. Latent Tuberculosis Infection Detection Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environment landscape
3.3.3. Pricing Analysis
3.3.4. Volume Analysis
Chapter 4. Latent Tuberculosis Infection Detection Market: Brand Estimates & Trend Analysis
4.1. Global Latent Tuberculosis Infection Detection Market: Brand Dashboard
4.2. Global Latent Tuberculosis Infection Detection Market: Brand Movement Analysis
4.3. Global Latent Tuberculosis Infection Detection Market by brand, Revenue
4.4. QFT-Plus (QuantiFERON-TB Gold Plus)
4.4.1. QFT-Plus (QuantiFERON-TB Gold Plus) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Latent Tuberculosis Infection Detection Market: Test Type Estimates & Trend Analysis
5.1. Global Latent Tuberculosis Infection Detection Market: Test Type Dashboard
5.2. Global Latent Tuberculosis Infection Detection Market: Test Type Movement Analysis
5.3. Global Latent Tuberculosis Infection Detection Market by Test Type, Revenue
5.4. Tuberculin Skin Test (TST)
5.4.1. Tuberculin Skin Test (TST) market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Interferon Gamma Released Assay (IGRA)
5.5.1. Interferon Gamma Released Assay (IGRA) market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis
6.1. Global Latent Tuberculosis Infection Detection Market: Application Dashboard
6.2. Global Latent Tuberculosis Infection Detection Market: Application Movement Analysis
6.3. Global Latent Tuberculosis Infection Detection Market by Application, Revenue
6.4. Household Contacts with Pulmonary TB
6.4.1. Household contacts with pulmonary TB market estimates and forecasts 2018 to 2030 (USD Million)
6.5. PLHIV
6.5.1. PLHIV market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Latent Tuberculosis Infection Detection Market: End-use Estimates & Trend Analysis
7.1. Global Latent Tuberculosis Infection Detection Market: End-use Dashboard
7.2. Global Latent Tuberculosis Infection Detection Market: End-use Movement Analysis
7.3. Global Latent Tuberculosis Infection Detection Market by End-use, Revenue
7.4. Diagnostic Laboratories
7.4.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Hospitals/Clinics
7.5.1. Hospitals/Clinics market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Academic & Research Institutions
7.6.1. Academic & research institutions market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Latent Tuberculosis Infection Detection Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use
8.1. Regional Dashboard
8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.9. Netherlands
8.4.9.1. Key country dynamics
8.4.9.2. Regulatory framework/ reimbursement structure
8.4.9.3. Competitive scenario
8.4.9.4. Netherlands market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.10. Belgium
8.4.10.1. Key country dynamics
8.4.10.2. Regulatory framework/ reimbursement structure
8.4.10.3. Competitive scenario
8.4.10.4. Belgium market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.11. Finland
8.4.11.1. Key country dynamics
8.4.11.2. Regulatory framework/ reimbursement structure
8.4.11.3. Competitive scenario
8.4.11.4. Finland market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.12. Luxembourg
8.4.12.1. Key country dynamics
8.4.12.2. Regulatory framework/ reimbursement structure
8.4.12.3. Competitive scenario
8.4.12.4. Luxembourg market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.4.13. Iceland
8.4.13.1. Key country dynamics
8.4.13.2. Regulatory framework/ reimbursement structure
8.4.13.3. Competitive scenario
8.4.13.4. Iceland market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.7. Singapore
8.5.7.1. Key country dynamics
8.5.7.2. Regulatory framework/ reimbursement structure
8.5.7.3. Competitive scenario
8.5.7.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.5.8. Bangladesh
8.5.8.1. Key country dynamics
8.5.8.2. Regulatory framework/ reimbursement structure
8.5.8.3. Competitive scenario
8.5.8.4. Bangladesh market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.6.2. Mexico
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.6.3. Argentina
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. QIAGEN
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. BIOMÉRIEUX
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Oxford Immunotec
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. SD Biosensor, INC.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Wantai BioPharm
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Lionex GmbH
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Sanofi
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Serum Institute of India Pvt. Ltd
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. ARKRAY, Inc.
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Par Pharmaceutical, Inc.
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings